Influenza polymerase uses short capped primers snatched from nascent Pol II transcripts to initiate transcription of viral mRNAs. Here we describe crystal structures of influenza A and B polymerase bound to a capped primer in a configuration consistent with transcription initiation ('priming state') and show by functional assays that conserved residues from both the PB2 midlink and cap-binding domains are important for positioning the capped RNA. In particular, mutation of PB2 Arg264, which interacts with the triphosphate linkage in the cap, significantly and specifically decreases cap-dependent transcription. We also compare the configuration of the midlink and cap-binding domains in the priming state with their very different relative arrangement (called the 'apo' state) in structures where the potent cap-binding inhibitor VX-787, or a close analogue, is bound. In the 'apo' state the inhibitor makes additional interactions to the midlink domain that increases its affinity beyond that to the cap-binding domain alone. The comparison suggests that the mechanism of resistance of certain mutations that allow virus to escape from VX-787, notably PB2 N510T, can only be rationalized if VX-787 has a dual mode of action, direct inhibition of capped RNA binding as well as stabilization of the transcriptionally inactive 'apo' state.
Influenza polymerase uses short pan class="Chemical">capped primers snatched from nascent Pol II transcripts to initiate transcription of viral mRNAs. Here we describe crystal structures of influenza A and B polymerase bound to a capped primer in a configuration consistent with transcription initiation ('priming state') and show by functional assays that conserved residues from both the PB2 midlink and cap-binding domains are important for positioning the capped RNA. In particular, mutation of PB2 Arg264, which interacts with the triphosphate linkage in the cap, significantly and specifically decreases cap-dependent transcription. We also compare the configuration of the midlink and cap-binding domains in the priming state with their very different relative arrangement (called the 'apo' state) in structures where the potent cap-binding inhibitor VX-787, or a close analogue, is bound. In the 'apo' state the inhibitor makes additional interactions to the midlink domain that increases its affinity beyond that to the cap-binding domain alone. The comparison suggests that the mechanism of resistance of certain mutations that allow virus to escape from VX-787, notably PB2 N510T, can only be rationalized if VX-787 has a dual mode of action, direct inhibition of capped RNA binding as well as stabilization of the transcriptionally inactive 'apo' state.
Authors: Luc J Farmer; Michael P Clark; Michael J Boyd; Emanuele Perola; Steven M Jones; Alice Tsai; Marc D Jacobs; Upul K Bandarage; Mark W Ledeboer; Tiansheng Wang; Hongbo Deng; Brian Ledford; Wenxin Gu; John P Duffy; Randy S Bethiel; Dean Shannon; Randal A Byrn; Joshua R Leeman; Rene Rijnbrand; Hamilton B Bennett; Colleen O'Brien; Christine Memmott; Kwame Nti-Addae; Youssef L Bennani; Paul S Charifson Journal: ACS Med Chem Lett Date: 2017-01-20 Impact factor: 4.345
Authors: Stefan Reich; Delphine Guilligay; Alexander Pflug; Hélène Malet; Imre Berger; Thibaut Crépin; Darren Hart; Thomas Lunardi; Max Nanao; Rob W H Ruigrok; Stephen Cusack Journal: Nature Date: 2014-11-19 Impact factor: 49.962
Authors: Lili Xie; Charles Wartchow; Steven Shia; Kyoko Uehara; Micah Steffek; Robert Warne; James Sutton; Gladys T Muiru; Vincent H J Leonard; Dirksen E Bussiere; Xiaolei Ma Journal: J Biol Chem Date: 2015-11-11 Impact factor: 5.157
Authors: Eva Kowalinski; Chloe Zubieta; Andrea Wolkerstorfer; Oliver H J Szolar; Rob W H Ruigrok; Stephen Cusack Journal: PLoS Pathog Date: 2012-08-02 Impact factor: 6.823
Authors: Pavel V Afonine; Ralf W Grosse-Kunstleve; Nathaniel Echols; Jeffrey J Headd; Nigel W Moriarty; Marat Mustyakimov; Thomas C Terwilliger; Alexandre Urzhumtsev; Peter H Zwart; Paul D Adams Journal: Acta Crystallogr D Biol Crystallogr Date: 2012-03-16
Authors: Eric Thierry; Delphine Guilligay; Jan Kosinski; Thomas Bock; Stephanie Gaudon; Adam Round; Alexander Pflug; Narin Hengrung; Kamel El Omari; Florence Baudin; Darren J Hart; Martin Beck; Stephen Cusack Journal: Mol Cell Date: 2015-12-17 Impact factor: 17.970
Authors: Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read Journal: J Appl Crystallogr Date: 2007-07-13 Impact factor: 3.304
Authors: Tim Krischuns; Catherine Isel; Petra Drncova; Maria Lukarska; Alexander Pflug; Sylvain Paisant; Vincent Navratil; Stephen Cusack; Nadia Naffakh Journal: PLoS Pathog Date: 2022-05-23 Impact factor: 7.464
Authors: Amir Ghorbani; Michael C Abundo; Hana Ji; Kara J M Taylor; John M Ngunjiri; Chang-Won Lee Journal: J Virol Date: 2020-12-22 Impact factor: 5.103
Authors: David C McGowan; Wendy Balemans; Werner Embrechts; Magali Motte; Jeremy R Keown; Christophe Buyck; Jordi Corbera; Mario Funes; Laura Moreno; Ludwig Cooymans; Abdellah Tahri; Julien Eymard; Bart Stoops; Rudy Strijbos; Joke Van den Berg; Ervin Fodor; Jonathan M Grimes; Anil Koul; Tim H M Jonckers; Pierre Raboisson; Jérôme Guillemont Journal: J Med Chem Date: 2019-10-30 Impact factor: 7.446